Hepatitis C prevention and treatment among people who inject drugs: Global progress and future requirements

Knowledge market 3 (K3)
In programme
Wednesday, 23 November, 2022 - 16:50 to 18:20
View presentations

About

This session will bring together stakeholders to highlight:

1) the effectiveness of opioid agonist treatment and needle and syringe programs for the prevention of hepatitis C and HIV infection

2) Success in treatment as prevention for hepatitis C infection

3) Successful interventions to enhance testing and treatment for hepatitis C infection

4) The importance of peer support, peer research, and peer involvement in policy development.

Chair

Grebely
Jason
  • Professor,
  • The Kirby Institute,
  • Australia
Chang
Judy
  • Executive Director,
  • International Network of People Who Use Drugs,
  • London,
  • United Kingdom

Type

Tracks

Keywords

Presentations

Wednesday, 23 November

16:50
Oral presentation

1. Interventions to enhance prevention of hepatitis C and HIV infection

16:50 to 18:20
Knowledge market 3 (K3)
Julie Bruneau
Oral presentation

2. Treatment as prevention for hepatitis C infection: A key piece to the elimination puzzle

16:50 to 18:20
Knowledge market 3 (K3)
Matthew Hickman
Oral presentation

3. We have reached single-diagnosis and treatment for hepatitis C infection: What next?

16:50 to 18:20
Knowledge market 3 (K3)
Jason Grebely
Oral presentation

4. Community-led initiatives to enhance prevention and treatment for hepatitis C

16:50 to 18:20
Knowledge market 3 (K3)
Judy Chang
View the programme